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Summary Dabigatran, a direct thrombin inhibitor, is 
licensed for the prevention of venous thromboembolism 
after knee and hip replacement, the prevention of stroke 
and systemic embolism in patients with non-valvular 
atrial fibrillation and for the treatment of acute venous 
thromboembolism. As dabigatran has a favourable ben-
efit–risk profile, it is being increasingly used. Dabigatran 
differs from vitamin K antagonists as regards its phar-
macological characteristics and its impact on certain 
laboratory tests, and also in the lack of a direct antagonist 
that can reverse dabigatran-induced anticoagulation. In 
emergency settings such as acute bleeding, emergency 
surgery, acute coronary syndrome, thrombolysis for 
ischaemic stroke or overdosing, specific strategies are 
required. A working group of experts from various dis-
ciplines has developed strategies for the management of 
dabigatran-treated patients in emergency settings.
Keywords Dabigatran · Bleeding · Surgery · Acute coro-
nary syndrome · Stroke
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Dabigatran – Patientenmanagement in speziellen 
Situationen
Zusammenfassung Dabigatran, ein direkter Thrombin-
Inhibitor, ist zur Prophylaxe venöser Thromboembolien 
nach Knie- oder Hüftgelenkersatz, zur Prophylaxe von 
Schlaganfällen und systemischer Embolien bei nicht-
valvulärem Vorhofflimmern zugelassen und zur Thera-
pie der akuten venösen Thromboembolie. Aufgrund des 
günstigen Nutzen/Risiko-Profils wird eine zunehmende 
Zahl von Patienten mit Dabigatran behandelt. Dabi-
gatran unterscheidet sich von den Vitamin K-Antago-
nisten durch seine pharmakologischen Eigenschaften, 
seine Beeinflussung von Labortests, aber auch durch 
fehlende Antagonisierbarkeit. In Notfallsituationen, wie 
beispielsweise bei einer akuten Blutung, einer Notope-
ration, einem akuten Koronarsyndrom, der Thrombolyse 
bei ischämischem Schlaganfall oder einer Überdosie-
rung, sind spezielle Strategien erforderlich. Eine Arbeits-
gruppe, die sich aus Experten unterschiedlicher Fach-
richtungen zusammensetzt, hat Therapiestrategien zum 
Management akuter Notfallsituationen bei Patienten, die 
mit Dabigatran behandelt werden, erarbeitet.
Schlüsselwörter Dabigatran  · Blutung  · Operation  · 
Akutes Koronarsyndrom · Schlaganfall
Background
Dabigatran has been approved for primary prevention 
of venous thromboembolism in adult patients after elec-
tive hip or knee replacement, for the prevention of stroke 
and systemic embolism in patients with non-valvular 
atrial fibrillation, and for the treatment of acute venous 
thromboembolism. Due to its simpler management and 
its favourable risk/benefit profile compared with vitamin 
K antagonists, the number of dabigatran-treated patients 
is steadily increasing.
As with any drug that inhibits coagulation, bleeding 
can also occur with dabigatran. At present, no direct anti-
dotes that can specifically reverse the effects of dabiga-
tran are available, even though there is intense research 
going on. In this report, strategies for the management 
of acute bleeding, either spontaneously or in the context 
of surgery or injury, are addressed. In addition, manage-
ment strategies for specific acute clinical settings includ-
ing ischaemic stroke, acute coronary syndrome and 
overdosing are discussed. The recommendations relate 
exclusively to the specific dabigatran effects and are 
based on a very low level of scientific evidence. General 
measures that are also applied in non-dabigatran-treated 
patients in the above-mentioned settings will not be dis-
cussed. The general management of bleeding should be 
performed according to guidelines of national and inter-
national societies or local institutions. In this context, we 
refer to recent publications [1–4].
Overview of phase III studies
Knee or hip replacement
Dabigatran 150 mg or 220 mg once daily (OD) is as effec-
tive as enoxaparin 40 mg OD or 30 mg twice (BID) daily 
in the prevention of postsurgical venous thromboembo-
lism. Dabigatran and enoxaparin treatments also confer 
comparable risks of severe bleeding (RR 0.72 (0.27–1.89), 
p = 0.50; 0.73(0.38–1.40), p = 0.34, respectively) [5].
Acute venous thromboembolism
In the treatment of acute venous thromboembolism 
enoxaparin followed by dabigatran 150  mg BID is as 
effective and safe as enoxaparin followed by a vitamin K 
antagonist (incidence of recurrent venous thromboem-
bolism: 2.4 % vs 2.1 %; HR 1.1 (0.65–1.82); incidence of 
major bleeding: 1.6 % vs 1.9 %; HR 0.82 (0.45–1.48)) [6].
Non-valvular atrial fibrillation
For the prevention of stroke or systemic embolism, treat-
ment with dabigatran 150  mg BID is significantly more 
effective than warfarin (annual incidences: 1.11 % vs 
1.71 %; p < 0.001). The lower dose of dabigatran (110 mg 
BID) is equally effective as warfarin (annual incidences: 
1.54 % vs 1.71 %). The risk of severe bleeding is similar in 
patients treated with the high dose of dabigatran dose as 
compared with warfarin therapy (3.32 % vs 3.57 %) and 
is significantly lower with the lower dose of dabigatran 
(2.87 % vs 3.57 %). Intracranial bleeding was observed 
significantly less often with dabigatran than with warfa-
rin (high dose: 0.31 %; low dose: 0.23 %; warfarin: 0.76 %; 
p < 0.001). Fatal intracranial bleeding occurred infre-
quently (dabigatran 150  mg BID: 13 cases, dabigatran 
110 mg BID: 11 cases; warfarin: 32 cases) Mortality due 
to intracranial bleeding was similar across all treatment 
groups (35 %, 41 % and 36 %, respectively). Gastrointes-
tinal bleeding occurred more frequently with dabiga-
tran 150 mg BID than with warfarin (annual incidences: 
1.56 % vs 1.07 %) [7–10].
In five phase III studies approximately 27,500 patients 
were treated with either dabigatran or warfarin over 6–36 
months [11]. The 30-day mortality due to severe bleed-
ing was 9 % with dabigatran and 13 % with warfarin 
(odds ratio 0.66 (0.44–1.0); p = 0.051). Overall, 1162 cases 
of severe bleeding occurred with dabigatran or warfa-
rin treatment. Only 10 of these patients were treated 
with prothrombin complex concentrates (PCC) and 11 
patients received recombinant factor VIIa (rFVIIa). Only 
1 patient underwent haemodialysis. These small patient 
numbers preclude conclusions on the efficacy of these 
therapies.
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The magnitude of the effect of dabigatran on the aPTT 
depends on the reagent. A normal aPTT does not fully 
preclude a clinically relevant dabigatran level [16], but 
is commonly accepted as evidence for a lack of antico-
agulatory effects of dabigatran in the peri-interventional 
setting.
Both the prothrombin time and the activated clotting 
time can be prolonged during dabigatran treatment. The 
sensitivity of the prothrombin time towards dabigatran 
is low and substantial differences between various pro-
thrombin time reagents have been found [17]. The low 
sensitivity of the activated clotting time restricts its use 
under routine conditions [18].
Reversal
Data from animal and in-vitro experiments will not be 
discussed, because they are irrelevant from a clinical 
point of view. An antidote that can antagonise the effects 
of dabigatran, idarucizumab, has been shown to be safe 
in a phase I study [19].
Dabigatran is lipophilic and binds to activated char-
coal. A 57-year-old suicidal woman ingested 11  g dabi-
gatran and survived after she was treated with activated 
charcoal (plus gastric lavage) [20]. Due to the rapid 
absorption of dabigatran, the administration of activated 
charcoal is only reasonable within the first 2 (to 4) h after 
ingestion.
Dabigatran is dialysable and several case reports show 
that haemodialysis is effective prior to emergency surgery 
[20] or in the case of life-threatening bleeding [22, 23]. 
Approximately two thirds of dabigatran can be removed 
from the circulation within 4 h. The practical aspects as 
regards haemodialysis are summarised in Table 1.
As a thrombin inhibitor dabigatran affects the final 
step of the coagulation cascade and thrombin-medi-
ated platelet activation. Interventions that interfere with 
the coagulation cascade above this level do not appear 
promising, at least from a theoretical point of view. The 
application of fresh-frozen plasma or PCC normalized 
the results of ex-vivo coagulation tests or improved the 
bleeding tendency neither in healthy volunteers given 
dabigatran nor in dabigatran-treated patients [12, 24]. 
Pharmacological features
Dabigatran etexilate is administered orally and is rapidly 
hydrolysed to the active drug dabigatran. Dabigatran 
inhibits directly and reversibly both free and clot-bound 
thrombin. The peak dabigatran plasma level is reached 
approximately 2 h after ingestion. Allowing for the consid-
erable inter-individual variety, these peak plasma levels 
reach, on average, 175 ng/mL in the context of long-term 
dabigatran administration at a dose of 150 mg BID. The 
trough levels are 91 ng/mL after 12 h [12]. Approximately 
80 % of dabigatran is excreted unaltered via the kidneys. 
The half-life of dabigatran in plasma depends on the kid-
ney function: at a creatinine clearance (CrCl) of greater 
than 80  mL/min, 50–80  mL/min or 30–50  mL/min, the 
half-life is 13 h, 15 h and 18 h, respectively, and increases 
to 27 h at a CrCl of less than 30 mL/min. Due to low pro-
tein binding, dabigatran is dialyzable. P-glycoprotein 
inhibitors such as amiodarone, verapamil, cyclosporine 
or ketoconazole increase dabigatran plasma levels, while 
P-glycoprotein inducers such as rifampicine and carba-
mazepin have the opposite effect.
Effects on laboratory tests
Dabigatran affects all coagulation and thrombin-depen-
dent platelet function tests [13]. The extent depends on 
the dose, the time interval between dabigatran ingestion 
and blood sampling and the kidney function. Treatment 
with dabigatran does not routinely require laboratory 
monitoring. In the case of bleeding, in the peri-opera-
tive setting, or prior to major surgery or invasive proce-
dure, coagulation tests could be helpful. The choice of 
test for the estimation of a dabigatran effect depends on 
availability, linearity of the dose-effect curve and stan-
dardisation. Assessment of thrombin activity using a 
chromogenic substrate or the ecarin clotting time is not 
addressed, as these test systems are only available in spe-
cialised coagulation laboratories.
The thrombin clotting time (TT) measures the conver-
sion of fibrinogen to fibrin, which is the final step in the 
coagulation cascade. The TT is prolonged in the pres-
ence of thrombin inhibitors such as dabigatran. The TT 
prolongation is directly proportional to the dabigatran 
concentration. At a dabigatran plasma concentration of 
200 ng/mL (peak level), the TT is approximately 15-fold 
prolonged. A normal TT value precludes a clinically rel-
evant dabigatran level. Conversely, a prolonged TT can 
be indicative for (residual) dabigatran activity. However, 
the extent of a potential bleeding risk cannot be deduced 
from TT prolongation. The plasma concentration of dabi-
gatran can also be measured by calibrated TTs, such as 
the Hemoclot test system. The lower detection limit is 
20 ng/mL [14, 15].
Dabigatran also prolongs the activated partial throm-
boplastin time (aPTT). At a dabigatran level of 200  ng/
mL, the aPTT is of approximately 2.5-fold prolonged. 
The dose-effect curve flattens at higher dabigatran levels. 
Table 1 Haemodialysis in dabigatran-treated patients
Procedure, duration Intermittent: haemodialysis
Continuous haemofiltration (in unstable patients): 
3–4 h each
Access Haemofiltration catheter
Dialysis membrane In haemodialysis: mid-flux or high-flux membranes 
(there are currently no data for low-flux membranes)
Anticoagulation Citrate
Blood flow rate 250–300 mL/min
Dialysate flow rate 500–800 mL/min
Assessment of the 
treatment effect
TT, Hemoclot, aPTT
TT thrombin clotting time, aPTT activated partial thromboplastin time
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applied. A medical history to exclude disorders associ-
ated with an increased risk of bleeding such as von Wil-
lebrand disease, thrombocytopenia or impaired liver 
and kidney function should be obtained. Drugs affecting 
platelet function such as aspirin, clopidogrel, non-steroi-
dal anti-inflammatory drugs or selective serotonin and 
norepinephrine re-uptake inhibitors should be discon-
tinued, unless their use is mandatory. Kidney function 
should be monitored in patients with renal disease or 
dehydration. Once bleeding has stopped, treatment with 
dabigatran can be resumed, possibly at a lower dose.
Major bleeding includes gastrointestinal haemor-
rhage, bleeding requiring transfusion of red blood cells 
or bleeding associated with a significant decrease in 
the haemoglobin level, critical organ bleeding (with 
the exception of the central nervous system; see next 
paragraph on life-threatening bleeding) or severe post-
traumatic haemorrhage. Major bleeding requires discon-
tinuation of dabigatran, rapid location of the bleeding 
site and local haemostatic measures. Patients receiving a 
platelet function inhibitor should be given platelet con-
centrates. The extent of bleeding management is depen-
dent on the severity of bleeding and on the condition of 
the patient. Dabigatran-sensitive laboratory tests (TT or 
Hemoclot) and the CrCl allow estimating the duration of 
the dabigatran effect. If bleeding cannot be stopped by 
the aforementioned measures, it has to be regarded life-
threatening and the following interventions should be 
applied (see also Fig. 1).
Life-threatening bleeding includes bleeding leading 
to haemodynamic collapse, bleeding after polytrauma, 
Three-factor concentrates contain coagulation factors II, 
IX and X, four-factor concentrates also factor VII.
Compelling data that would suggest the use of acti-
vated PCC, which contain activated coagulation fac-
tors II and VII are missing. rFVIIa induces the formation 
of thrombin on the surface of platelets in the absence 
of tissue factor. To date, there is no evidence that rFVIIa 
has a significant impact on dabigatran-related coagula-
tion impairment, neither in volunteers nor in bleeding 
patients.
As a caveat, the possibility of excessive coagulation 
activation resulting in thrombotic complications includ-
ing stroke, myocardial infarction or pulmonary embo-
lism must be taken into account when administering 
coagulation factors, in particularly activated factors.
Management of acute bleeding (Fig. 1)
The management of acute bleeding depends upon sever-
ity, location and dose and time point of last dabigatran 
intake.
Minor bleeding such as mild nose bleeding, bruises or 
gum bleeding usually does not necessitate discontinua-
tion of dabigatran treatment. Another medical consulta-
tion is required if symptoms deteriorate.
Minor but clinically relevant bleeding includes pro-
longed and/or extensive nose bleeding, large (post-
traumatic) haematomas, haematuria or metrorrhagia. 
In these instances treatment with dabigatran needs to be 
discontinued and local haemostatic measures should be 
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switched to a vitamin K antagonist. For patients who have 
received a stent and in whom triple therapy is required, 
recommendations for dabigatran are lacking. In RE-LY, 
38 % of patients received concomitant platelet function 
inhibitors [25]. In these patients bleeding occurred more 
frequently both with dabigatran and warfarin as com-
pare with patients given dabigatran or warfarin alone. 
However, the benefit of dabigatran over warfarin was 
retained. The combination of dabigatran with a platelet 
function inhibitor will be recommended in the 2014 ESC 
guidelines.
Management of ischaemic stroke
In general, in patients with ischaemic stroke throm-
bolysis should only be performed in the absence of any 
dabigatran effect. The use of thrombolytic agents can 
be considered in patients who have a normal TT (when 
quantitatively assessed in diluted plasma samples) and/
or a normal aPTT.
Management of overdosing
In the case of dabigatran overdose, close surveillance 
is recommended along with forced diuresis to decrease 
the dabigatran levels as quickly as possible. If dabigatran 
was ingested within the last 2 h (to 4 h), administration 
of activated charcoal should be considered. Other mea-
sures should only be considered in case of bleeding (see 
chapter on “Acute bleeding”).
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or intracranial haemorrhage. In addition to general 
intensive-care measures, we recommend administration 
of an activated PCC (initial dose 50  IE/kg body weight; 
repeated dosing if necessary; maximal dose 200  IE/kg 
body weight per day). If an activated PCC is not available, 
a 4-factor PCC should be given (initial dose 25 IE/kg body 
weight; may be repeated once or twice). Haemodialysis 
can be considered taking into account feasibility and 
risk. Ultimately, rFVIIa (initially 90  µg/kg body weight; 
repeated dosing) can be given.
Management of emergency surgery
In case of emergency surgery, dose and time point of 
last dabigatran intake, extent, type and urgency of sur-
gery and the clinical condition of the patient have to be 
taken into consideration. Dabigatran treatment has to be 
discontinued. CrCl has to be measured and a dabigatran-
sensitive coagulation assay (TT or Hemoclot) needs to be 
performed.
If TT is normal, one can assume that there is no effect 
of dabigatran and dabigatran-specific measures are not 
useful. A prolonged TT does not correlate with the risk of 
bleeding. The risk of delaying surgery has to be balanced 
against the potential risk of dabigatran-associated bleed-
ing. In most cases surgery can be postponed for some 
hours allowing the dabigatran plasma level to decrease. 
In rare cases such as in patients with ruptured aortic 
aneurysm, aortic dissection or polytrauma, results of 
coagulation assays should not be awaited and the patient 
should undergo surgery immediately.
In case of intra-operative bleeding, administration 
of activated PCC can be considered in addition to local 
haemostatic and general bleeding measures. The pos-
sible benefits and the feasibility of haemodialysis should 
be considered and weighed against its risks. Ultimately, 
rFVIIa can be given.
Management of ST-segment elevation myocardial 
infarction/high-risk non-ST elevation acute 
coronary syndrome
Dabigatran needs to be discontinued. In patients with 
ST-segment elevation myocardial infarction or high-risk 
non-ST elevation acute coronary syndrome, the coro-
nary intervention should be performed according to cur-
rent guidelines. Specific coagulation tests are not useful, 
because the urgent need for the intervention precludes 
waiting for the test results. To minimise the bleeding risk, 
interventions using a radial approach are preferable.
When an elective percutaneous coronary intervention 
is performed, dabigatran should be suspended on the 
day of intervention. Angiography should be performed 
with or without coronary intervention according to rou-
tine protocols.
Patients, who have received a stent and have a per-
sisting indication for oral anticoagulation, should be 
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